Module now available Long-read sequencing analysis See the research

Terms of Service

License for Research Use

WARNING: THIS PRODUCT AND SERVICE IS LICENSED FOR RESEARCH USE ONLY.  THIS PRODUCT AND SERVICE HAS NOT BEEN APPROVED BY OR CLEARED WITH THE FOOD AND DRUG ADMINISTRATION OR ANY OTHER AGENCY OR ORGANIZATION.  THIS PRODUCT AND SERVICE IS NOT APPROVED FOR USE AS A STAND ALONE DIAGNOSTIC PROCEDURE.

PLEASE NOTE THAT YOUR USE OF AND ACCESS TO PATHOGENOMIX PRODUCTS AND SERVICES (EACH DEFINED BELOW) ARE SUBJECT TO THE FOLLOWING TERMS; IF YOU DO NOT AGREE TO ALL OF THE FOLLOWING, YOU MAY NOT USE OR ACCESS THE PATHOGENOMIX PRODUCTS OR SERVICES IN ANY MANNER.  USE OF THE SERVICES IS EXPRESSLY CONDITIONED UPON YOUR (OR THE COMPANY THAT YOU REPRESENT) (“USER”) ASSENT TO ALL THE TERMS AND CONDITIONS OF THIS AGREEMENT, TO THE EXCLUSION OF ALL OTHER TERMS. IF THE TERMS OF THIS AGREEMENT ARE CONSIDERED AN OFFER, ACCEPTANCE IS EXPRESSLY LIMITED TO SUCH TERMS.

The software products and services, including but not limited to RipSeq Mixed, RipSeq Single and RipSeq NGS (collectively the “Pathogenomix Products”),of Pathogenomix, Inc. (“Pathogenomix”), with an address at  877 Cedar St STE 150, Santa Cruz, CA 95060, United States of America, are made available to the User upon the following terms and conditions:

  1. Terms of Use. By accessing or using the Pathogenomix Products the User agrees:
  2. The Pathogenomix Products have not been approved or cleared by the U.S. Food and Drug Administration (“FDA”) for marketing or sale in the United States and are being provided to the User for research purposes only.
  3. The Pathogenomix Products are not to be used or relied upon by User as a diagnostic procedure without confirmation of the diagnosis by another medically-established diagnostic product or procedure.
  4. The labeling on or associated with the Pathogenomix Products, including the first software screen which reads “FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES”, is required by FDA regulations and may not to be altered or removed by User.
  5. Pathogenomix makes no representation that the results provided by the Pathogenomix Product satisfy or will satisfy any requirements of any governmental body or other organization, including, but not limited to, any requirements of the FDA, Centers for Medicare and Medicaid Services (“CMS”), Clinical Laboratory Improvements Act (“CLIA”) or the International Organization for Standardization (“ISO”).
  6. User takes responsibility to ensure that the results provided by the Pathogenomix Product are adequate to meet User’s regulatory / certification requirements.  All requirements of any governmental body or other organization, including, but not limited to, any requirement of the FDA, CMS, CLIA or ISO are the sole responsibility and obligation of User.
  7. The Research Licensee Fee paid to Pathogenomix by User is intended to recover the costs of manufacture, research, development and handling in accordance with applicable FDA regulations.
  8. User shall not provide to Pathogenomix or use the Pathogenomix Products to analyze any information, identifiers, or other data relating to an identifiable person who can be directly or indirectly identified by reference to any identifier, including without limitation any “personal data”, “personal health information”, “individually identifiable health information” or any other “personal information” as defined by applicable law, rule or regulation.
  9. User acknowledges and agrees that Pathogenomix may anonymously aggregate data arising from use of the Pathogenomix Software and Services, including without limitation, aggregation of pathogen identification data, aggregation of most popular approved references for each sequence, and may use and distribute such aggregations.
  10. Life Technologies Corporation and its affiliates shall not be responsible for the content, of, use of, maintenance, support or performance of the Pathogenomix Products.
  11. License and Intellectual Property Rights.
  12. Subject to the terms and conditions of this agreement, Pathogenomix hereby grants to User a non-transferable, non-sublicensable, non-exclusive, limited right and license to use the Pathogenomix Products and Services for its internal research purposes only.
  13. User agrees that any and all Intellectual Property Rights contained in or relating to the Pathogenomix Products are and shall remain the exclusive property of Pathogenomix and/or its licensors.  “Intellectual Property Rights” includes, but is not limited to, any right or protection existing from time to time in a specific jurisdiction, whether registered or not, under any patent law or other invention or discovery law, copyright law, publicity, performance or moral rights law, trade secret law, confidential information law, right of privacy, industrial design law, trademark law, unfair competition or trade practices law, or other similar laws, and includes any such rights recognized in judicial decisions under common law or equity.
  14. Nothing in this License intends to transfer any Pathogenomix Intellectual Property Rights to, or to vest any such Intellectual Property Rights in, User.
  15. User is only entitled to the limited use of the Pathogenomix Intellectual Property Rights granted to User in this agreement. User agrees that this agreement is personal and not transferable by User.
  16. User agrees not to take any action to jeopardize, limit or interfere with the Pathogenomix Intellectual Property Rights.
  17. User agrees that any unauthorized use of the Pathogenomix Intellectual Property Rights is a violation of this License as well as a violation of intellectual property laws, including without limitation copyright laws and trademark laws.
  18. Pathogenomix reserves the right, at its sole discretion, to modify or replace any of the provisions of this agreement, or change, suspend, or discontinue the Pathogenomix Products and Services (including without limitation, the availability of any feature, database, or content) at any time, with or without notice.
  19. User will not, and will not permit any third party to: reverse engineer, decompile, disassemble or otherwise attempt to discover the source code, object code or underlying structure, ideas or algorithms of the Pathogenomix Products or Services or any software, documentation or data related thereto (except to the extent that enforcement of the foregoing restriction is expressly prohibited by applicable statute); modify, translate, or create derivative works based on the Pathogenomix Products or Services; use the Pathogenomix Products or Services for timesharing or service bureau purposes or for any purpose other than its own use for the benefit of end users; or use the Pathogenomix Products or Services other than in accordance with this agreement and in compliance with all applicable laws and regulations (including but not limited to any applicable privacy laws), and intellectual property.
  20. As defined in FAR section 2.101, any software and documentation provided by Pathogenomix are “commercial items” and according to DFAR section 252.227‑7014(a)(1) and (5) are deemed to be “commercial computer software” and “commercial computer software documentation.”  Consistent with DFAR section 227.7202 and FAR section 12.212, any use modification, reproduction, release, performance, display, or disclosure of such commercial software or commercial software documentation by the U.S. Government will be governed solely by the terms of this agreement and will be prohibited except to the extent expressly permitted by the terms of this agreement. 
  21. Disclaimer of Warranties.
  22. THE PATHOGENOMIX PRODUCTS ARE PROVIDED “AS IS.”  PATHOGENOMIX DISCLAIMS ALL REPRESENTATIONS, WARRANTIES, GUARANTEES AND CONDITIONS, EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT, OR ANY IMPLIED WARRANTIES ARISING OUT OF A COURSE OF PERFORMANCE, DEALING, OR TRADE USAGE.
  23. PATHOGENOMIX DOES NOT REPRESENT OR WARRANT THAT THE PATHOGENOMIX PRODUCTS WILL ALWAYS BE AVAILABLE, ACCESSIBLE, UNINTERRUPTED, TIMELY, SECURE, ACCURATE, COMPLETE, ERROR-FREE, OR WILL OPERATE WITHOUT PACKET LOSS, NOR DOES PATHOGENOMIX WARRANT ANY CONNECTION TO OR TRANSMISSION FROM THE INTERNET, OR ANY QUALITY OF TRANSMISSIONS OF DATA MADE THROUGH THE PATHOGENOMIX PRODUCTS.
  24. PATHOGENOMIX DOES NOT WARRANT, GUARANTEE OR REPRESENT THAT THERE ARE NO VIRUSES OR OTHER HARMFUL COMPONENTS IN ANY OF THE HTML CODE OR OTHER SOFTWARE, OR PRODUCTS, PROVIDED BY PATHOGENOMIX, OR THAT THE PATHOGENOMIX PRODUCTS WILL EMPLOY SUFFICIENT SECURITY METHODS.
  25. USER ACKNOWLEDGES THAT THE ENTIRE RISK ARISING OUT OF THE USE OR PERFORMANCE OF THE PATHOGENOMIX PRODUCTS REMAINS WITH USER TO THE MAXIMUM EXTENT PERMITTED BY LAW.
  26. SOME JURISDICTIONS DO NOT ALLOW SOME OF THE EXCLUSIONS SET FORTH IN THIS SECTION; THUS SOME OF THESE EXCLUSIONS MAY NOT APPLY TO USER.    
  27. Limitation of Liability.
  28. IN NO EVENT SHALL PATHOGENOMIX, ITS AFFILIATES, PARENT COMPANIES, SUBSIDIARIES, OFFICERS, DIRECTORS, EMPLOYEES, AGENTS OR SOFTWARE LICENSORS BE LIABLE WHETHER IN CONTRACT, WARRANTY, TORT (INCLUDING NEGLIGENCE, WHETHER ACTIVE, PASSIVE OR IMPUTED), PRODUCT LIABILITY OR STRICT LIABILITY OR ANY OTHER THEORY, FOR ANY INDIRECT, INCIDENTAL, SPECIAL OR CONSEQUENTIAL DAMAGES, INCLUDING WITHOUT LIMITATION ANY LOSS OF DATA, SERVICE INTERRUPTION, COMPUTER FAILURE OR PECUNIARY LOSS, ARISING OUT OF THE USE OR INABILITY TO USE THE PATHOGENOMIX PRODUCTS, INCLUDING ANY DAMAGES RESULTING THEREFROM, EVEN IF PATHOGENOMIX HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.  IN NO EVENT WILL PATHOGENOMIX’S LIABILITY TO USER OR TO ANY THIRD PARTY EXCEED THE AMOUNTS PAID BY USER TO PATHOGENOMIX.
  29. USER’S ONLY RIGHT WITH RESPECT TO ANY PROBLEMS OR DISSATISFACTION WITH THE PATHOGENOMIX PRODUCTS IS TO CEASE USE.
  30. SOME JURISDICTIONS DO NOT ALLOW SOME OF THE EXCLUSIONS SET FORTH IN THIS SECTION; THUS SOME OF THESE EXCLUSIONS MAY NOT APPLY TO USER.
  31. General Terms and Conditions. 
  32. Electronic Signatures.  User agrees to the use of electronic communication in order to enter into contracts, place orders and create other records and to the electronic delivery of notices, policies and records of transactions.  User waives any rights or requirements under any laws or regulations in any jurisdiction which require an original (non-electronic) signature or delivery or retention of non-electronic records, to the extent permitted under applicable mandatory law.
  33. Investigation and Disclosure to Governmental Authorities.  User agrees that Pathogenomix may disclose information provided by User, or about User or User’s use of Pathogenomix Products, in compliance with lawful process, or to comply with law enforcement requests or other legal, governmental or regulatory orders or actions.
  34. Relationship of Parties.  Each party is an independent contractor, and nothing in this License creates any partnership, joint venture, agency, franchise, or other relationship between the parties.
  35. Force Majeure.  Pathogenomix not shall be liable under this License by reason of any failure or delay in the performance of its obligations in this License on account of strikes, shortages, riots, insurrection, fires, flood, storm, explosions, acts of God, war, governmental action, labor conditions, earthquakes, telecommunications interference or failure, or any other cause, which is beyond the reasonable control of Pathogenomix.
  36. Assignment.  Pathogenomix may assign this License in whole or in part without User’s approval.  This License shall be binding on, and inure to the benefit of, and be enforceable against, the parties and their respective successors and assigns.
  37. Independent Investigation.  User acknowledges that User has read this License and agrees to all its terms and conditions. User represents and agrees that User has independently evaluated the Pathogenomix Products and is not relying on any representation, guarantee, or statement other than as set forth in this License.
  38. Waiver.  No waiver or consent by any party of or to any breach or default of this License by the other party will be effective unless evidenced in writing.  No waiver or consent effectively given as aforesaid will operate as a waiver or consent of or to any other right or other or further breach or default in relation to the same or any other provision of this License.  Pathogenomix’s failure to enforce User’s strict performance of any provision of this License will not constitute a waiver of our right to subsequently enforce such provision or any other provision of this License.
  39. Notice.  Every notice, consent or other communication provided for in this License or arising in connection therewith shall be emailed to the parties.  Either party may change its email address by giving written notice to the other party to that effect.  Notices sent to Pathogenomix by email should be addressed to Pathogenomix at sales@Pathogenomix.com. Every such notice, consent or other communication delivered shall be deemed to have been given and received on the day such communication was delivered and every notice, consent or other communication transmitted by email shall be deemed to have been given and received on the day such communication was transmitted by email,  provided however that if such day falls on a weekend or statutory holiday, then the notice, consent or other communication shall be deemed to have been given and received on the next business day following such day.
  40. Survival.  Should any term or provision of this License be deemed invalid, void or unenforceable either in its entirety or in a particular application, the remainder of this License shall remain in full force and effect.
  41. Interpretation.  In this License, unless there is something in the subject matter or context inconsistent therewith: (a) words, in the singular number include the plural and such words shall be construed as if the plural had been used; (b) words in the plural include the singular and such words shall be construed as if the singular had been used; (c) words importing the use of any gender shall include all genders where the context or party referred to shall require, and the rest of the sentence shall be construed as if the necessary grammatical and terminological changes had been made; (d) the word “person” shall include an individual, a trustee, executor, administrator or legal representative, a partnership, an association, a body corporate, a trust, an unincorporated organization and a corporation; and (e) the word “writing” includes e-mail communications.
  42. Language. The original English version of this License may have been translated into other languages. In the event of inconsistency or discrepancy between the English version and any other language version of this License, the English language version shall prevail.
  43. Governing Law.  This License shall be governed by and construed in accordance with the laws of California, United States of America without regard to the conflict of law rules applicable therein, and shall be treated in all respects as if it was made and entered into in Santa Cruz, California, USA.  The parties to this License hereby irrevocably and unconditionally submit to the exclusive jurisdiction of the courts having jurisdiction over contracts made and entered into and to be performed in California, United States of America.  User agrees not to bring claims on a representative, class member basis, or as a private attorney general, and agrees not to assert any claims against Pathogenomix unless such claims are asserted by User no later than one year following the date that User’s claim or cause of action arose, at which point said claims are forever barred.
  44. Resolution of Disputes. Any dispute, controversy, or claim arising out of, related to, concerning or in connection with this License or to the breach, termination or invalidity thereof, or to the relationship of the parties hereto, shall be finally settled and determined solely and exclusively by arbitration administered by JAMS under its then current Commercial Arbitration Rules.  The seat of arbitration shall be Santa Cruz, California, Unites States of America, and the language of arbitration shall be English.  The written award of the arbitrators shall be final and binding upon the parties, and judgment on or enforcement of the award so rendered may be sought, had or entered in any court having jurisdiction.
  45. Export.  Usershall comply with the U.S. Foreign Corrupt Practices Act and all applicable export laws, restrictions and regulations of the U.S. Department of Commerce, and any other applicable U.S. and foreign authority.
  46. Entire License.  This License supersedes all prior written and oral representations, arrangements, negotiations, understandings and Licenses between the parties relating to the subject matter hereof and sets forth the entire complete and exclusive agreement and understanding between the parties hereto relating to the subject matter hereof.